Daniel Stoltze
Optometrist · Fallston, MDNPI 1114909348
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,887 of the $7,836 with a category attached, or 87.9%. It is spread thinly across 27 manufacturers, the largest accounting for just 18.6% — the pattern of someone who eats at a lot of different presentations. Among optometrist clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 206 payments — averaging $38.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$1K
- Johnson & Johnson Surgical Vision, Inc.$1K
- Bausch & Lomb Americas Inc.$1K
- Tarsus Pharmaceuticals, Inc.$772
- AbbVie$502
- Glaukos Corporation$475
- plus $3K from 21 others
Across 68 payments — averaging $33.97 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Notal Vision, Inc.$2K
What the payments were for
- Speaking & faculty fees$2073%
- Travel & lodging$7439%
- Food & beverage$6,88788%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 40 | $1,454 |
| Johnson & Johnson Surgical Vision, Inc. | 7 | $1,050 |
| Bausch & Lomb Americas Inc. | 24 | $1,018 |
| Tarsus Pharmaceuticals, Inc. | 16 | $772 |
| AbbVie | 21 | $502 |
| Glaukos Corporation | 10 | $475 |
| Sun Pharmaceutical Industries Inc. | 30 | $434 |
| Johnson & Johnson Vision Care, Inc. | 6 | $323 |
| Dompe US, Inc. | 10 | $281 |
| Harrow Eye, LLC | 6 | $231 |
| Notal Vision, Inc. | 2 | $207 |
| Rxsight Inc | 3 | $151 |
| Novartis | 1 | $113 |
| Oyster Point Pharma, Inc. | 4 | $109 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $99 |
| ABB Con-cise Optical Group LLC | 3 | $97 |
| Optovue, Inc. | 1 | $97 |
| Coopervision Inc. | 4 | $74 |
| Biotissue Holdings Inc. | 4 | $68 |
| Apellis Pharmaceuticals, Inc. | 2 | $64 |
| Maculogix, Inc. | 3 | $60 |
| Mallinckrodt Hospital Products Inc. | 2 | $48 |
| Astellas Pharma US Inc | 1 | $33 |
| Sight Sciences, Inc. | 1 | $24 |
| Rayner Intraocular Lenses Limited | 1 | $20 |
| Visioneering Technologies, Inc. | 1 | $16 |
| Thea Pharma Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tecnis 1-piece IOL$868
- Tecnis Multifocal Family of 1-piece IOLS$868
- Tecnis Symfony IOL$868
- XIIDRA$456
- XDEMVY$368
- MIEBO$343
- iDoseTR$227
- Acuvue$226
- TOTAL30$147
- LUMIGAN$123
- DURYSTA$123
- XEN GLAUCOMA TREATMENT SYSTEM$123
- Precision7$122
- VEVYE$120
- TRYPTYR$110
- INFUSE SVS$109
- DAILIES$105
- AIR OPTIX$105
- Clareon$102
How this compares
$7,836 in reported general payments places this provider in the 95th percentile of 790 optometrist providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 18 | $27,849 |
| XdemvyLotilaner | 11 | $20,282 |
| RestasisCyclosporine | 20 | $19,251 |
| Latanoprost | 37 | $477 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Xiidra | $1,018 | $27,84918 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $772 | $20,28211 claims |
| AbbVieRestasis | $502 | $19,25120 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 790 optometrist providers in Maryland.
Other optometrist in Fallston
- Susan LathropFulton$337K
- Timothy EarleyOakland$276K
- Padmini NathanFrederick$199K
- Alan GlazierRockville$87K
- Andrew MorgensternBethesda$62K
- Devin SasserSilver Spring$40K
- Rizwana IqbalEllicott City$34K
- Brian WoolfPasadena$19K
- Vickie FangGaithersburg$17K
- Aaron WeinsteinWaldorf$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.